Bevacizumab (Avastatin)
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
Translational Oncology 2025 November [Link] Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuejoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro-Sibilot, Olivier Molinier, Hervé Léna, Isabelle Monnet, Franck Morin, Valérie Gounant, Gérard Zalcman Abstract We investigated whether angiogenesis-related microRNAs (miRNAs) predict survival in patients with pleural mesothelioma…
Read MoreSuccessful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports
Case Reports in Oncology 2025 January 30 [Link] Tomonobu Koizumi, Shintaro Kanda, Nodoka Sekiguchi, Takuro Noguchi, Sei-Ichiro Eda, Hiroto Kitahara Abstract Introduction: Peritoneal mesothelioma is an extremely rare malignancy of the peritoneum. It has a poor prognosis, and the optimal systemic chemotherapy remains controversial. Here, we report two cases of peritoneal mesothelioma with long-term survival…
Read MoreComparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
JAMA Network Open 2022 March 1 [Link] Tomer Meirson, Francesca Pentimalli, Francesco Cerza, Giovanni Baglio, Steven G Gray, Pierpaolo Correale, Marija Krstic-Demonacos, Gal Markel, Antonio Giordano, David Bomze, Luciano Mutti Abstract Importance: Some recently proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, yet their impact on quality of life and overall survival…
Read MoreEfficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Frontiers in Oncology 2021 April 20 [Link] Oscar Arrieta, Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Saul Campos, Rodrigo Catalán, Herman Soto-Molina, Silvia Guzmán Vázquez, Osvaldo Díaz-Álvarez, Victor Martínez-Pacheco, Jenny G Turcott, Maritza Ramos-Ramírez, Luis Cabrera-Miranda, Feliciano Barrón, Andrés F Cardona Abstract Background: Malignant pleural mesothelioma (MPM) is rare and aggressive neoplasia, with a poor prognosis; furthermore, the…
Read MoreMST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
British Journal of Cancer 2019 February 11 [Link] Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R16, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G Abstract BACKGROUND: The Mesothelioma Avastin Cisplatin Pemetrexed…
Read MoreNintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo
Clinical cancer research 2018 May 3 [Link] Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirók A, Garay T, Stiglbauer A, Helbich TH, Groger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is an…
Read MoreDeterminants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
Cancer Medicine 2018 February 26 [Epub ahead of print] [Link] Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC Abstract This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density,…
Read MoreAnti-tumor immunotherapy in malignant pleural mesothelioma
Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date.…
Read MoreA review of bevacizumab in the treatment of malignant pleural mesothelioma
Future Oncology 2017 September [Epub ahead of print] [Link] Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab,…
Read MoreThe Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma
International Journal of Molecular Services 2017 November [Link] Pulford E, McEvoy J, Hocking A, Prabhakaran S, Griggs K, Klebe S Abstract Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes, with poor overall survival and quality of life. Limited targeted treatment strategies exist due to restricted knowledge of pathogenic pathways. Vasculogenic mimicry (VM)…
Read More